Market research
H02.SG HAW PAR CORP LTD
Current ticker: H02.SG
SG SGD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 3B
- P/E ratio
- 12.34
- Analyst target
- 14.6
- Dividend yield
- 3.1%
- Beta
- 0.16
Profile
Instrument facts
- Exchange
- SG
- Currency
- SGD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- ISIN
- SG1D25001158
- Market cap
- 3B
- P/E ratio
- 12.34
- Analyst target
- 14.6
- Dividend yield
- 3.1%
- Beta
- 0.16
About
About HAW PAR CORP LTD
Haw Par Corporation Limited, together with its subsidiaries, manufactures, markets, and trades in healthcare products in Singapore, The Association of Southeast Asian Nations countries, other Asian countries, and internationally. It manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands; and invests in quoted securities. The company also owns and leases various investment properties. In addition, it provides family and tourist oriented leisure activities primarily in the form of oceanariums. Further, the company is involved in the property development; and owning and letting properties; letting out of office spaces; and management support services. Haw Par Corporation Limited was incorporated in 1969 and is based in Singapore.
Research context
HAW PAR CORP LTD appears in PyInvesting’s Singapore Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- SGD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the H02.SG discussion.
5 years, 6 months ago
Haw Par Corporation Limited is currently in a long term uptrend where the price is trading 14.8% above its 200 day moving average.
From a valuation standpoint, the stock is 213.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 26.6.
Haw Par Corporation Limited's total revenue rose by 154.9% to $111M since the same quarter in the previous year.
Its net income has increased by 829.9% to $120M since the same quarter in the previous year.
Finally, its free cash flow fell by 99.8% to $28K since the same quarter in the previous year.
Based on the above factors, Haw Par Corporation Limited gets an overall score of 3/5.